Neumora Therapeutics Inc (NASDAQ:NMRA) has a beta value of 3.97 and has seen 1.25 million shares traded in the last trading session. The company, currently valued at $1.74B, closed the last trade at $11.17 per share which meant it lost -$0.28 on the day or -2.45% during that session. The NMRA stock price is -88.0% off its 52-week high price of $21.00 and 25.43% above the 52-week low of $8.33. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.34 million shares traded. The 3-month trading volume is 901.49K shares.
The consensus among analysts is that Neumora Therapeutics Inc (NMRA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Sporting -2.45% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NMRA stock price touched $11.17 or saw a rise of 12.32%. Year-to-date, Neumora Therapeutics Inc shares have moved -34.49%, while the 5-day performance has seen it change -8.96%. Over the past 30 days, the shares of Neumora Therapeutics Inc (NASDAQ:NMRA) have changed -17.53%. Short interest in the company has seen 9.01 million shares shorted with days to cover at 7.62.
Wall Street analysts have a consensus price target for the stock at $24.5, which means that the shares’ value could jump 54.41% from current levels. The projected low price target is $20.0 while the price target rests at a high of $29.0. In that case, then, we find that the current price level is -159.62% off the targeted high while a plunge would see the stock gain -79.05% from current levels.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
Figures show that Neumora Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 20.76% over the past 6 months, with this year growth rate of 59.23%, compared to 17.50% for the industry.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders own 28.00% of the company shares, while shares held by institutions stand at 61.92% with a share float percentage of 86.00%. Investors are also buoyed by the number of investors in a company, with Neumora Therapeutics Inc having a total of 139.0 institutions that hold shares in the company.
